Live Earnings Conference Call: Corvus Pharmaceuticals will host a live Q2 2025 earnings call on August 7, 2025 at 4:30PM ET. Follow this link to get details and listen to Corvus Pharmaceuticals' Q2 2025 earnings call when it goes live. Get details. Corvus Pharmaceuticals (CRVS) Competitors $4.17 -0.12 (-2.80%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$4.18 +0.00 (+0.12%) As of 08/6/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, DYN, SANA, and RCUSShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), Dyne Therapeutics (DYN), Sana Biotechnology (SANA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Sana Biotechnology Arcus Biosciences Corvus Pharmaceuticals (NASDAQ:CRVS) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Does the media refer more to CRVS or CDTX? In the previous week, Corvus Pharmaceuticals and Corvus Pharmaceuticals both had 2 articles in the media. Cidara Therapeutics' average media sentiment score of 0.86 beat Corvus Pharmaceuticals' score of 0.13 indicating that Cidara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRVS or CDTX? Corvus Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 259.71%. Cidara Therapeutics has a consensus price target of $57.29, suggesting a potential downside of 7.59%. Given Corvus Pharmaceuticals' higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is CRVS or CDTX more profitable? Corvus Pharmaceuticals' return on equity of -24.04% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -24.04% -13.90% Cidara Therapeutics N/A -73.04%-54.28% Which has more risk and volatility, CRVS or CDTX? Corvus Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Which has higher valuation & earnings, CRVS or CDTX? Corvus Pharmaceuticals has higher earnings, but lower revenue than Cidara Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.26Cidara Therapeutics$302K4,138.96-$169.83M-$29.47-2.10 Do institutionals and insiders have more ownership in CRVS or CDTX? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCorvus Pharmaceuticals and Cidara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$292.45M$3.01B$5.57B$9.47BDividend YieldN/A2.41%4.31%4.13%P/E Ratio-4.2616.5729.3723.99Price / SalesN/A314.79444.1896.63Price / CashN/A42.1735.8458.51Price / Book8.187.818.085.58Net Income-$62.29M-$54.52M$3.26B$265.35M7 Day PerformanceN/A0.41%0.45%-0.07%1 Month Performance6.92%9.93%4.83%1.76%1 Year Performance26.75%15.18%30.28%25.39% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.4144 of 5 stars$4.17-2.8%$15.00+259.7%+39.0%$292.45MN/A-4.2630News CoverageUpcoming EarningsCDTXCidara Therapeutics3.3666 of 5 stars$62.68+1.3%$57.29-8.6%+454.0%$1.25B$1.27M-2.1390Upcoming EarningsCVACCureVac4.4633 of 5 stars$5.42-0.7%$6.83+26.1%+60.3%$1.22B$579.18M5.89880News CoveragePositive NewsUpcoming EarningsAUPHAurinia Pharmaceuticals2.1566 of 5 stars$8.89-0.4%$11.50+29.4%+106.6%$1.21B$235.13M31.75300Trending NewsEarnings ReportInsider TradeAnalyst RevisionPRAXPraxis Precision Medicines1.699 of 5 stars$55.65-6.0%$94.11+69.1%-11.9%$1.21B$8.55M-5.19110Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.1763 of 5 stars$28.92-0.9%$24.40-15.6%+53.4%$1.18B$1.02B37.081,940Positive NewsSRPTSarepta Therapeutics4.614 of 5 stars$13.86+16.2%$51.42+271.0%-88.6%$1.17B$1.90B-5.151,372Trending NewsDYNDyne Therapeutics3.4934 of 5 stars$9.31-6.4%$40.63+336.4%-73.3%$1.13BN/A-2.59100Upcoming EarningsAnalyst ForecastGap DownTrading HaltedSANASana Biotechnology3.4261 of 5 stars$4.88-1.4%$9.17+87.8%-14.3%$1.12BN/A-5.55380News CoverageRCUSArcus Biosciences2.1204 of 5 stars$9.85-3.7%$21.29+116.1%-34.5%$1.08B$258M-2.35500News CoverageEarnings Report Related Companies and Tools Related Companies Cidara Therapeutics Alternatives CureVac Alternatives Aurinia Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Calliditas Therapeutics AB (publ) Alternatives Phibro Animal Health Alternatives Sarepta Therapeutics Alternatives Dyne Therapeutics Alternatives Sana Biotechnology Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts